OVERVIEW
Happy Saturday

Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Here are the Stocktwits Top 25 Lists for this week:

S&P 500
ST Top 25 S&P 500 💪

SPONSORED BY OFFERPAD
$OPAD Brokerage Solutions Division Hits Stride in Q1 2026

Offerpad (NYSE: $OPAD) just hit a milestone: in Q1 2026 alone, its HomePro agent program referred more qualified sellers to partner agents than in all of 2025.

HomePro sits inside Offerpad’s Brokerage Solutions division and connects engaged, motivated sellers with agents ready to close. These aren’t cold leads. They’re sellers who’ve already consulted with an Offerpad advisor, explored their options, and chosen the listing path. HomePro agents get them handed off with perks already included: seller warranty, packing kit, and interim storage.

Powering the growth: SCOUT and HENRY, Offerpad’s newly launched AI platforms that match sellers to the right solution faster and with greater precision.

For investors tracking $OPAD’s evolution from a single cash offer solution to a multi-solution real estate platform, this is the brokerage revenue diversification story taking shape in real time.

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

NASDAQ 100
The Large-Cap Nasdaq 100 🤖

ST EDITOR’S PICKS
What We Are Reading and Watching 🗞️ 👀 

THE CASHTAG AWARDS
The BIGGEST night in Finance. May 4th. NYSE.

The Cashtag Awards are built by the Stocktwits community and it wouldn’t be the same without you in the room!

We’re offering a limited number of fully comped tickets for members who want to show up, represent, and help make this night as special as it should be.

Want to celebrate with us on May 4th?

RUSSELL 2000
The Growth-Centric Russell 2000 🦐

Top Dawg Of The Week 🐶

Tango Therapeutics’s Oncology Pipeline Validated: The precision medicine developer saw its valuation reset higher on Monday as positive clinical data from a peer’s pancreatic cancer trial renewed investor confidence in the specific biological mechanism underlying its own lead drug candidates. $TNGX ( ▲ 6.39% ) surged +27% through Wednesday, touching multi-year highs as the market priced in a higher probability of success for its upcoming solid tumor readouts.

The RIP: $TNGX shares hit $25.33 on Wednesday, representing a 27% gain from the prior week’s close. Catalyst driven by Leerink Partners raising its price target to $28 from $19 while maintaining an Outperform rating. The firm noted that Phase 3 data from Revolution Medicines’ daraxonrasib validated the target market for Tango’s vopimetostat. The company ended its last quarter with $343M in cash, providing a runway through 2028 despite a $101M annual net loss, according to SEC filings.

Holders should monitor clinical updates for TNG462 and TNG908 scheduled for later this year, as the stock remains highly sensitive to single-catalyst risk in the PRMT5 inhibitor space. Investors in $RVMD and $IDYA are most exposed to this same therapeutic vertical, where validation of brain-penetrant oncology compounds is driving sector-wide re-ratings. While the insider sale of 27,000 shares by the President of R&D on April 1 signaled profit-taking, the broad analyst consensus remains a Moderate Buy with a top-tier price target of $30. 🧬

Get In Touch 📬

Help us deliver the best content possible by completing this brief survey. 📝

Want to see some change? Email Kevin Travers your feedback; follow him on Stocktwits.

Terms & Conditions 📝

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋